促性腺激素释放激素及多巴胺对斜带石斑鱼生长激素分泌及其mRNA表达的调控

研究斜带石斑鱼生长激素分泌及其mRNA表达的调控规律对于性别分化的控制、临床药物的选择,以及石斑鱼的增养殖等均具有重要的理论意义和实践意义。本文应用静态孵育系统,采用放射免疫测定法和化学发光液相杂交实验,研究GnRH和DA对斜带石斑鱼GH分泌、GHmRNA合成的调控作用。100nmol／LsGnRH作用斜带石斑鱼脑垂体碎片1也4h,明显促进GH的释放和GHmRNA的合成,并具有时间依存性;10nmol／L～1μmol／LsGnRH作用1h能明显促进斜带石斑鱼脑垂体释放GH,促进GHmRNA的合成,表现出明显的剂量效应。100nmol／L、1μmol／LmGnRH作用1h以一定的剂量依存方式促进GH的释放、促进GHmRNA的合成,但mGnRH的效应比相应剂量的sGnRH的作用弱。APO为DA受体的非选择性激动剂,不同剂量APO对斜带石斑鱼脑垂体碎片的作用结果显示,10nmol／L-1μmol／L APO以剂量依存方式促进斜带石斑鱼脑垂体碎片释放GH、促进GHmRNA的合成：1μmol／LAPO作用12h以上明显促进GH的释放和GHmRNA的合成,并随时间的延长而增加。与sGnRH对斜带石斑鱼GH释放、GHmRNA合成的作用相比,APO的作用较弱。本文研究结果证实GnRH和DA能促进斜带石斑鱼脑垂体GH释放和GHmRNA合成。     

重组斜带石斑鱼生长激素及其抗血清在放射免疫测定中的应用

将斜带石斑鱼(Epinephelus coioides)生长激素成熟多肽cDNA序列克隆到质粒pRSET,与6x组氨酸等原核编码序列融合获得重组质粒pRGH6,转入大肠杆菌BL21(DE3),获得高效表达,表达量占细菌总蛋白的43％。免疫印迹证明表达产物为含斜带石斑鱼生长激素的融合蛋白,Ni^2 亲合层析柱纯化融合蛋白,以此为抗原免疫家兔制备特异性的抗血清。以纯化的重组生长激素和特异性的抗血清建立斜带石斑鱼生长激素的放射免疫测定法,该方法的灵敏度、特异性和重复性均达到测定血液生长激素的水平。研究了多巴胺的受体激动剂阿扑吗啡对静态孵育斜带石斑鱼脑垂体碎片释放生长激素的影响,结果表明,阿扑吗啡能以剂量依存方式促进斜带石斑鱼垂体释放生长激素。     

下丘脑生长抑素神经元的研究

1967年,Krulich等发现,下丘脑提取物有抑制生长激素(GH)释放的作用,首先提出,下丘脑存在生长激素释放抑制因子(SRIF)。10年后,Brazeau等成功地分离、提纯、鉴定了SRIF,它为14个氨基酸组成的多肽,对GH释放抑制作用具有剂量反应关系。之后,人们又陆续发现了12肽、28肽、25肽的SRIF,它们和14肽的SRIF有相同的氨基酸顺序片段,并对GH有较强的抑制作用。随着基因工程的发展,学者们得以推断出SRIF的前体和前肽原。研究表明,各种哺乳动物具有生物活性的部分差别不大,其羧基端14个氨基酸序列为保守区。目前,将SRIF基因克隆并合成SRIF已成为现实,将SRIF广泛药用于临床已为期不远。     

尼罗罗非鱼生长激素及其受体的cDNA克隆与mRNA表达的雌雄差异

尼罗罗非鱼(Oreochromis niloticus)雌雄鱼生长差异明显,为了探讨其原因,本文采用RT-PCR方法克隆了尼罗罗非鱼生长激素(Growthhormone,GH)及其受体(Growth hormone receptor,GHR)的cDNA序列,并应用半定量RT-PCR方法比较了雌、雄尼罗罗非鱼垂体GHmRNA、肝脏GHRmRNA、肌肉GHRmRNA的表达差异。序列分析表明:GH开放阅读框为615bp,共编码204个氨基酸;GHR开放阅读框为1908bp,共编码635个氨基酸。以RT-PCR方法研究了GH、GHR在各组织的分布情况,结果表明:GH仅在垂体中检测到有表达,而GHR在所检测的18种组织中均有表达,其中以肝脏、肌肉、性腺、下丘脑、胸腺表达量较高。以半定量RT-PCR方法进一步比较了雌、雄尼罗罗非鱼垂体GHmRNA、肝脏GHRmRNA、肌肉GHRmRNA的表达量,结果表明:雄鱼垂体GHmRNA和肝脏GHRmRNA的表达量均显著高于雌鱼,肌肉GHRmRNA的表达量则无显著差异,推测垂体GHmRNA和肝脏GHRmRNA表达的雌雄差异是尼罗罗非鱼雌雄生长差异的主要原因之一。     

生长激素mRNA在蓝太阳鱼垂体外组织中的表达分布

应用半定量RT PCR方法和Southern杂交技术,系统地研究了生长激素(GH)基因在蓝太阳鱼垂体外组织中的表达情况。在建立检测蓝太阳鱼GHmRNA表达的半定量RT PCR扩增条件之后,分别对蓝太阳鱼雄性幼鱼(6月龄)和雄性成鱼(1年龄)的12个组织部位中GHmRNA的表达进行了检测。结果表明,除了在垂体之外,还在肌肉、性腺、鳃、心脏、脑、肾脏6个组织检测到GHmRNA的表达,但各组织间的表达水平存在差异,而在脾脏、肝脏、胃3个组织未检测到表达;肌肉组织中的表达水平从幼鱼到成鱼后明显提高,同时观察到在幼鱼和成鱼的性腺组织中存在着较高水平的表达。本研究表明,GH基因在蓝太阳鱼的垂体外组织中存在着广泛的表达,由此提示,蓝太阳鱼GH可能以旁分泌或自分泌的方式对其生长繁殖起着重要的作用。     

6种重要经济鱼类生长激素完整cDNA的克隆和序列分析

通过RT-PCR、3′RACE、5′-RACE方法,从6种重要经济鱼类——大眼鳜(Siniperca kneri)、石斑鱼(Epinephelus coioides)、黄鳝(Monopterus albus)、鲶鱼(Silurus asotus)、泥鳅(Misgurnus anguillicaudatus)和方正银鲫(Carassius auratus gibelio Bloch,Fang Zheng crucian carp)中克隆了生长激素(Growth Hormone,GH)的完整cDNA序列(除石斑鱼序列外,其他生长激素序列均系第一次克隆),并详细分析了其序列特征。测序结果显示,克隆的6种GH cDNA长度依次为953bp、1023bp、825bp、1082bp、1154bp和1180bp,它们均包含一个长度为600个左右核苷酸的完整阅读框,分别编码一个200个左右氨基酸的蛋白：大眼鳜、石斑鱼和黄鳝GH为204个氨基酸,鲶鱼GH为200个氨基酸,泥鳅和方正银鲫GH为210个氨基酸。这6种蛋白序列与其他已知的鱼类GH序列都有较高的同源性,特别是与相同目的鱼类序列相比。通过序列比对,在这些蛋白序列内鉴定了许多保守的氨基酸残基,其中的大多数聚集而成5个保守域。基于这6种鱼类序列的编码区和其他鱼类的GH编码序列进行分子系统学分析,结果(MP和NJ树)与根据形态特征构建的系统发育树基本一致,特别是在硬骨鱼类较大分类阶元(目间、目以上)的系统发育研究方面比较一致,尽管仍存在一定差异,说明生长激素基因的编码区应该在硬骨鱼类系统发育研究领域得到更多的重视。     

慢病毒载体介导GHRH基因在小鼠肌肉组织表达及对动物生长的影响

人与动物体内生长激素受生长激素释放激素(Growth Hormone Releasing Hormone,GHRH)与生长激素抑制激素(Somatostatin,SST)两种因子共同调节,在体内表达外源GHRH,可以提高体内GH基础水平,进而达到促进体内GH释放,加速动物生长的效果.对慢病毒载体系统加以改造,使之成为C...     

斜带石斑鱼生长激素/催乳素家族基因cDNAs的分子克隆及其进化意义

从斜带石斑鱼垂体提取总。RNA,再取其50ng合成SMART cDNA。从所构建的垂体SMART cDNA质粒文库中筛选到生长激素／催乳素基因家族的2个成员的全长cDNA片段：生长激素(GH)基因全长为938bp,编码204个氨基酸;催乳素基因(PRI．)全长为1429bp,编码212个氨基酸。采用计算机软件Mega 2和CLUSTAL W1．64b对9种鱼的生长激素／催乳素基因家族的3个成员(GH、PRL和生长催乳素SL)的氨基酸序列进行系统分析,构建NJ分支系统树,对于序列中的插入／缺失位点则采用Pairaise Deletion,1000次自展(Bootstrap)分析计算各节点支持率。根据3个基因的氨基酸序列构建的系统树表明,石斑鱼与金头鲷、金鲈和牙鲆聚成一类,虹鳟与大马哈鱼聚成一类,鲫鱼与鲶鱼聚成一类,鳗鲡成另外一类。根据石斑鱼全长cDNA推断的氨基酸序列比较表明,SL相对GH和PRL有较高的保守性。石斑鱼的GH、PRL和SL的氨基酸同源性在24％～31％,但其C-端的氨基酸同源性较高,尤其是C-端的3个Cys是严格保守的。其中SL与GH的同源性(30．8％)高于与PRL的同源性(25．6％),GH和PRL的同源性最低(24．1％)。     

新的生长激素释放激素类似肽Pro-hGHRH(1-44)-Gly-Gly-Cys的重组和比较活性*

目的:为了寻找高活性和长半衰期生的GHRH类似肽。方法:通过使用独特的酸敏感水解位点Asp-Pro的原核表达系统,构建了新的Pro-hGHRH(1-44)-Gly-Gly-Cys类似肽。通过重组细菌裂解、包含体洗涤、乙醇分级沉淀、酸水解、SP-Sephadex C-25和Sephadex G-10柱层析等技术,纯化了高纯度的Pro-hGHRH(1-44)-Gly-Gly-Cys肽。通过使用SDS-PAGE、离子化质谱、雌大鼠垂体和人流产胎儿垂体,测定了多肽的纯度、分子量、生长激素释放活性。结果:Pro-hGHRH(1-44)-Gly-Gly-Cys肽分子量5373Da与实际值吻合,0.1~10 μg/ml的肽剂量不论是对人垂体还是大鼠垂体都增加了垂体生长激素的释放,大鼠垂体生长激素的释放具有剂量依赖性。与标准的hGHRH(1-40)肽比较,新的类似肽有较高的GH释放活性。结果也显示了,Pro-GHRH(1-44)-Gly-Gly-Cys与Pro-hGHRH(1-44)肽的GH释放活性无统计学差异。结论：新的类似肽有较好的生长激素释放活性、功能选择性和种属特异性。     

生长抑素的生物合成

1968年Krulin等观察到大鼠下丘脑含有抑制生长激素(GH)释放的物质;1973年Braz-eau等确定其是含14个氨基酸的多肽,定名为GH释放抑制激素或生长抑素(SS)。在脊椎动物SS选择性地分布于全身的细胞内,脑、胃肠和胰腺内含量最高,占25%、70%和5%。SS抑制腺垂体分泌GH、促甲状腺素等,可能也抑制神经垂体激素的释放、抑     

Dosing of growth hormone in growth hormone deficiency

Growth hormone (GH) treatment of GH-deficient (GHD) children is to a certain extent standardized worldwide. Recombinant 22 kDa GH is injected once daily by the subcutaneous route, mostly in the evening. The amount of GH injected (calculated per kg body weight or body surface area, expressed in terms of IU or mg) in prepubertal children mimics the known production rate (approximately 0.02 mg [0. 06 IU]/kg body weight per day). However, there is a wide variation in dosage, the reasons for which are partly unknown and partly due to national traditions and regimes imposed by authorities regulating reimbursement. The situation during puberty is less standardized, with most clinicians still not increasing the dosage according to known production rates. The results of these approaches in terms of adult height outcome are not always satisfactory. In order to achieve optimal height development during childhood, puberty and adulthood, strategies must be developed to individualize GH dosing according to set therapeutical goals taking into account efficacy, safety and cost. The implementation of prediction algorithms will help us to reach these goals. In addition, other response variables will have to be monitored during treatment in order to correct for deficits resulting from GHD.     

Factors influencing the growth hormone response to growth hormone-releasing hormone in children with idiopathic growth hormone deficiency

OBJECTIVE: To evaluate the factors influencing the growth hormone (GH) response to GH-releasing hormone (GHRH) test in idiopathic GH deficiency. METHODS: 28 patients aged 4.9 +/- 0.7 years with certain GH deficiency were given GHRH (2 microg/kg). RESULTS: The GH peak after GHRH was correlated negatively with age at evaluation (r = -0.37, p < 0.05) and body mass index (r = -0.44, p = 0.02), and positively with anterior pituitary height (r = 0.47, p = 0.02), GH peak after non-GHRH stimulation (r = 0.78, p < 0.0001) and spontaneous GH peak (r = 0.82, p = 0.007). It was lower in the patients aged >5 years than in the youngest (p = 0.04), but it was similar in the patients with and without features suggesting a hypothalamic origin. CONCLUSION: The GH response to GHRH test cannot be used to differentiate between hypothalamic and pituitary forms of idiopathic GH deficiency, probably because the GH response decreases after the first 5 years of life, whatever the origin of the deficiency.     

Cognitive function in growth hormone deficiency and growth hormone replacement

There is converging evidence from neuropsychological studies that growth hormone (GH) is associated with cognitive function. The aim of the current study was to review the existing neuropsychological literature for studies in which cognitive assessment had been conducted in patients with GH deficiency (GHD), and where change in cognitive function had been assessed following treatment with GH. Studies that have investigated relationships between GH and cognitive function and those that have developed methodological and statistical approaches that could be useful in future GH studies were identified. In this review, GH levels were found to be associated with cognitive function. Untreated individuals with GHD showed reliable impairment in memory and attentional functions when compared with matched controls. Appropriately designed prospective studies also indicated that cognitive function improved with GH treatment. It was concluded that individuals with GHD do show cognitive impairment and that this is ameliorated to some extent by GH treatment. It is now important to establish the clinical importance of these findings, and further work is required to understand better the nature, magnitude and meaning of GH-related cognitive impairments and improvements.     

Thyroid hormone and growth: relationships with growth hormone effects and regulation

For some years, research in the field of growth endocrinology has been mainly focused on growth hormone (GH). However, it appears that GH does not always control growth rate. For instance, it does not clearly influence intra-uterine growth: moreover, although the results of GRF or GH administration appear convincing in rats, pigs or heifers, this is not the case in chickens and lambs. In addition, GH does not always clearly stimulate somatomedin production, particularly diring food restriction and fetal life, and in hypothyroid animals or sex-linked dwarf chickens. In such situations, this phenomenon is associated with a reduced T3 production, suggesting a significant influence of thyroid function on GH action, and more generally, on body growth. In fact, numerous data demonstrate that thyroid hormone is strongly involved in the regulation of body growth. In species with low maturity at birth, such as the rat. T4 and T3 affect postnatal growth eleven days earlier than the appearance of GH influence. In contrast to GH, thyroid hormone significantly influences fetal growth in sheep. Moreover, the body growth rate is clearly stimulated by T3 in dwarf animals. In addition to its complex metabolic effects involved in the general mechanisms of body growth, thyroid hormone stimulates the production of growth factors, particularly EGF and NGF. Moreover, it affects GH and somatomedin production and also their tissue activity. All these results strongly suggest that it would be difficult to study GH regulation and physiological effects without taking thyroid function into account.     

Pharmacokinetics of growth hormone secretion in humans induced by growth hormone releasing hormone

This investigation compares the age- and sex-related changes in growth hormone (GH) response to growth hormone releasing hormone (GHRH) in normal subjects using an appropriate pharmacokinetic model. Twenty-five subjects (14 males and 11 females) aged 23-89 yr received a single intravenous bolus dose (1 microgram/kg) of GHRH-40 solution. Plasma GH concentration-time profiles are best characterized by a biexponential equation (or one-compartment model) with first-order release and disappearance rates and an equilibration lag time. The harmonic mean release rate half-life is similar for both sexes (males: 12.6 min vs. females; 11.4 min) but significantly different across age groups (23-35 yr: 7.2 min vs. 50-89 yr: 16.8 min). The mean disappearance rate half-life and GHRH-equilibration time lag for females (33.6 and 20.4 min, respectively) and the higher age group subjects (32.4 and 21.6 min, respectively) are significantly longer than those of males (22.8 and 9 min, respectively) and the lower age-group subjects (21.6 and 8.4 min, respectively). The mean metabolic clearance rate of GH is significantly lower (p less than 0.02) for females than for males (3.1 vs. 4.83 ml/hr.m2). However, the production rate and the amount of GH released by the pituitary for our subjects appear to be very similar for both males (8.7 micrograms/hr.m2 and 4.65 micrograms/m2) and females (9.33 micrograms/hr.m2 and 5.11 micrograms/m2).     

Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone

Binding of growth hormone (GH) to its receptor (GHR) is a well-studied example of molecular recognition between a cytokine and its receptor. Extensive mutagenesis studies and several crystal structures have defined the key interactive amino acid residues that are involved in binding and subsequent receptor dimerization. This review encompasses each of the three molecular recognition events involved in GHR activation, namely binding of GH to its two receptors and the interactions that occur between these receptors. Particular attention is given to species and ligand specificity of hormone binding and to the molecular recognition events involved in receptor activation, including the possibility that a conformational change in the receptor is required.